MIDAS VERDICT:

Gaining approval for new products is a notoriously slow process in the healthcare industry and Tristel has taken time to become established. Looking ahead however, sales and profits should accelerate – as coronavirus concentrates minds on the importance of effective hygiene. At £4.45, the shares have long-term potential.